{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-032300","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2023-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.677526+00:00","generated_at":"2026-06-13T10:30:01.207918+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"KalVista FY2023 net loss $92.9M; sebetralstat Phase 3 enrollment complete","bullets":["Phase 3 KONFIDENT trial achieved target enrollment (114 patients); data readout expected Q4 2023; NDA planned H1 2024.","Net loss FY2023 $92.9M ($3.33/share) vs $82.3M ($3.36/share); no revenue.","R&D expenses $80.3M (FY2023) vs $70.2M; G&A $30.6M vs $26.4M.","Cash, equivalents and marketable securities $149.4M; funded into 2025 after $58M registered direct offering.","Promoted Benjamin Palleiko to President; appointed Brian Pereira as Chairman."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-032300","json":"https://secwatch.observer/filing/0000950170-23-032300.json","markdown":"https://secwatch.observer/filing/0000950170-23-032300.md","text":"https://secwatch.observer/filing/0000950170-23-032300.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000095017023032300/0000950170-23-032300-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000095017023032300/kalv-20230707.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T10:30:01.207918+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7aeaabd3db9f9e7d72543bd9acc23249063558a2","claim":"KalVista Pharmaceuticals, Inc. reported fiscal year ended April 30, 2023 results: revenue No revenue was recognized, net income $92.9 million, EPS $(3.33) per weighted average basic and diluted share.","evidence_excerpt":"Net loss was $92.9 million, or $(3.33) per weighted average basic and diluted share for the fiscal year ended April 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000095017023032300/0000950170-23-032300-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended April 30, 2023"},{"label":"Revenue","value":"No revenue was recognized"},{"label":"Net income","value":"$92.9 million"},{"label":"EPS","value":"$(3.33) per weighted average basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c78d3f014fe8d6ac09004d01915227371ab0818a","claim":"KalVista Pharmaceuticals, Inc. reported three months ended April 30, 2023 results: revenue No revenue was recognized, net income $26.3 million, EPS $(0.77) per weighted average basic and diluted share.","evidence_excerpt":"Net loss was $26.3 million, or $(0.77) per weighted average basic and diluted share, for the three months ended April 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000095017023032300/0000950170-23-032300-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended April 30, 2023"},{"label":"Revenue","value":"No revenue was recognized"},{"label":"Net income","value":"$26.3 million"},{"label":"EPS","value":"$(0.77) per weighted average basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}